Galena to target Abstral as market leader for cancer pain

Tweet Galena Biopharma (NASDAQ:GALE) plans to make its recently acquired Abstral sublingual tablets the market leader for the treatment of breakthrough cancer pain (BTcP) in the U.S., matching the product’s performance in Europe. “Abstral is the latest and best-in-class drug for this indication,” president and CEO Mark Ahn says in an interview with BioTuesdays.com, noting [...]

Oramed readies oral insulin study in U.S.

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi-center Phase 2 clinical trial later this year. “Approving a clinical trial in the U.S. for oral insulin is a big deal,” [...]

BioLineRx pipeline returns to the winner’s circle

Tweet After disappointing investors in March by terminating a Phase 2/3 clinical trial of an anti-psychotic drug candidate for the treatment of schizophrenia, BioLineRx (NASDAQ:BLRX; TASE:BLRX) bounced back in April, posting positive Phase 2a results with an oral treatment for inflammatory bowel disease (IBD). “BioLineRx is not a binary company, but has a broad and [...]

Vaxil trial validates vaccine technology

Tweet Results of a recent clinical trial of Vaxil Bio’s (TASE:VAXL) ImMucin cancer vaccine in patients with multiple myeloma has validated the company’s VaxHit technology by demonstrating safety and a strong immune response in all patients. “This is not trivial for a first-in-man study,” CEO Lior Carmon says in an interview with BioTuesdays.com, referring to [...]

OnPoint’s Big-Data Equals Big Opportunity

Tweet OnPoint Medical Diagnostics (OTCQB:ONMD) is pioneering a “big-data” platform for delivering measurable, objective and automated quality assurance (QA) solutions for magnetic resonance imaging (MRI), with plans to expand its framework to include other modalities such as computed tomography (CT), ultrasound and mammography.  The company was founded in 2010 to commercialize imaging QA technologies developed [...]

BioDelivery on track for mid-year NDA filing

Tweet BioDelivery Sciences (NASDAQ:BDSI) is on track to file a new drug application with the FDA this summer for its Bunavail treatment for opioid dependence, one of two Phase 3 candidates in its product pipeline. “If all goes according to plan, in mid-2014, we should have an FDA decision on the approvability of Bunavail and [...]

International Stem Cell scores neuronal goal in treating Parkinson’s

Tweet Positive animal data reported by International Stem Cell (OTCBB:ISCO) last month brings the company one step closer to starting human testing of its stem cell technology to treat Parkinson’s disease. “We have established that the symptoms of Parkinson’s disease can be treated with our stem cell-derived neuronal cells,” Simon Craw, executive vice president, says [...]

OncoGenex’s OGX-427 drug gaining investor attention

Tweet Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second generation antisense drug, OGX-427. “We have data in bladder and prostate cancer with OGX-427 that, we believe, indicates clinical activity,” co-founder, president and CEO, Scott Cormack, says in [...]

Sucampo sees revenue from three continents by year end

Tweet Sucampo Pharmaceuticals (NASDAQ:SCMP) expects to be generating revenue from three continents – North America, Europe and Asia – by the end of 2013 from its two approved prostones products, Amitiza for gastrointestinal diseases and Rescula for ophthalmics. “This is in line with our goal to be a global company,” CFO Cary Claiborne says in [...]

All eyes on Ohr Pharma wet AMD study

Tweet Even though Ohr Pharmaceutical (OTCBB:OHRP) will be releasing results, in the current quarter, of a Phase 2 clinical trial in patients with cancer cachexia, all eyes are on a Phase 2 study of its squalamine eye drop to treat wet age-related macular degeneration (AMD), with interim results due at the end of the year. [...]

Next Page »